Biotechnology company using AI and cellular imaging to discover novel drugs through proprietary technology platform.MoreShow less
Profile & Fundamentals
Recursion Pharmaceuticals (RXRX.NASDAQ) Profile & Fundamentals
Review Recursion Pharmaceuticals reported earnings, valuation, balance sheet and ownership, with source tables and separate AI assessments.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Recursion Pharmaceuticals: Company Profile & Ownership
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Company profile record
Recursion Pharmaceuticals Inc
Common Stock · Health Care · Biotechnology
Company
- Company / asset
- Recursion Pharmaceuticals Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
Leadership & scale
- Full-time employees
- 600
- Fiscal year end
- December
- IPO date
- 2021-04-16
Fundamentals snapshot
- Market Cap
- USD 1.9B
- P/E
- --
- Revenue (Q3 26)
- USD 18.6M
- Profit (Q3 26)
- USD -119.0M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 74.7M
- Shares in public float
- 606.9M
- Insider ownership
- 1.74%
Reporting & identifiers
- Symbol
- RXRX.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US75629V1044
- Asset ID
- equity_24b377f3-f43f-576b-9216-ff7e3e56e9eb
Recursion Pharmaceuticals: Ownership
Shares Outstanding
Latest: 543.0M | Max: 543.0M | Min: 22.0M
Latest reported ownership snapshot
Float Shares
111.76%
606.9M latest reported shares
Insider Ownership
1.74%
Latest reported insider stake
Short Float
0.30%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2019-01-01 | 22,000,000 |
| 2020-01-01 | 167,056,100 |
| 2021-01-01 | 169,369,000 |
| 2022-01-01 | 185,669,700 |
| 2023-01-01 | 233,158,200 |
| 2024-01-01 | 336,036,000 |
| 2025-01-01 | 526,719,700 |
| 2026-01-01 | 543,001,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 50,304,691 | 8.07% | 2026-06-30 |
| ARK Investment Management LLC | 41,337,632 | 6.63% | 2026-06-30 |
| State Street Corp | 34,706,130 | 5.57% | 2026-06-30 |
| Vanguard Portfolio Management, LLC | 31,131,599 | 4.99% | 2026-06-30 |
| ARK Innovation ETF | 24,149,356 | 3.87% | 2026-10-29 |
| Baillie Gifford & Co Limited. | 23,487,907 | 3.77% | 2026-06-30 |
| Vanguard Capital Management, LLC | 22,765,940 | 3.65% | 2026-06-30 |
| Scottish Mortgage Ord | 18,174,384 | 2.92% | 2026-07-31 |
| State Street® SPDR® S&P® Biotech ETF | 17,824,766 | 2.86% | 2026-10-30 |
| Vanguard MStar Total Stk Mkt Idx Invest | 15,997,100 | 2.57% | 2026-09-30 |
| ARK Genomic Revolution ETF | 15,939,819 | 2.56% | 2026-10-29 |
| Geode Capital Management, LLC | 13,819,135 | 2.22% | 2026-06-30 |
| SoftBank Group Corp | 13,636,515 | 2.19% | 2026-06-30 |
| iShares Russell 2000 ETF | 12,959,157 | 2.08% | 2026-10-30 |
| Vanguard Small Cap Index | 11,453,189 | 1.84% | 2026-09-30 |
Recursion Pharmaceuticals: Earnings, Profitability & Valuation
Latest Financials Filed On
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Recursion's financial performance highlights the erratic reality of an early-stage drug developer that has not yet commercialized a medicine. For the twelve months ending June 30, 2026, revenue stood at $54.9 million against an operating deficit of $544 million. Because the company depends on sporadic milestone payments from partners rather than steady product sales, revenue plunged nearly 60% year-over-year in the second quarter of 2026 after earlier project phases wrapped up. However, reported losses are beginning to narrow as management enforces strict spending discipline. Operating expenses fell considerably in recent quarters, reflecting post-merger streamlining and lower data purchase costs. Even with these savings, cash generation remains negative, meaning incoming partner payments cushion spending rather than achieving self-sufficiency.
Recursion's financial performance highlights the erratic reality of an early-stage drug developer that has not yet commercialized a medicine. For the twelve months ending June 30, 2026, revenue stood at $54.9 million against an operating deficit of $544 million. Because the company depends on sporadic milestone payments from partners rather than steady product sales, revenue plunged nearly 60% year-over-year in the second quarter of 2026 after earlier project phases wrapped up. However, reported losses are beginning to narrow as management enforces strict spending discipline. Operating expenses fell considerably in recent quarters, reflecting post-merger streamlining and lower data purchase costs. Even with these savings, cash generation remains negative, meaning incoming partner payments cushion spending rather than achieving self-sufficiency.
Revenue, Net Income, and Free Cash Flow
Latest: USD 74.7M | Max: USD 74.7M | Min: USD -644.8M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability margins remain deeply negative, reflecting an R&D-heavy business where laboratory running costs vastly exceed early partnership payments. In fiscal 2025, gross margin registered at negative 62%, while operating margins remained below negative 300% due to ongoing laboratory overhead and clinical trial expenses. These severe deficits are a natural feature of pre-commercial biotechnology rather than a temporary slump. High-throughput automated screening carries significant fixed costs that cannot be scaled down easily when milestone payments pause. Lasting profit margins will only appear once internally owned drug candidates secure regulatory approval or yield substantial commercial sales royalties.
Profitability margins remain deeply negative, reflecting an R&D-heavy business where laboratory running costs vastly exceed early partnership payments. In fiscal 2025, gross margin registered at negative 62%, while operating margins remained below negative 300% due to ongoing laboratory overhead and clinical trial expenses. These severe deficits are a natural feature of pre-commercial biotechnology rather than a temporary slump. High-throughput automated screening carries significant fixed costs that cannot be scaled down easily when milestone payments pause. Lasting profit margins will only appear once internally owned drug candidates secure regulatory approval or yield substantial commercial sales royalties.
Profitability Margins
Latest: -62.0% | Max: 100.0% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
-62.0%
Gross profit / revenue
Operating Margin
-867.9%
Operating income / revenue
Net Margin
-863.4%
Net income / revenue
FCF Margin
-506.5%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2019-12-31 | 1,711,000 | -62,525,000 | -60,952,000 |
| 2020-12-31 | 3,413,000 | -87,006,000 | -52,134,000 |
| 2021-12-31 | 10,000,000 | -178,074,000 | -198,412,000 |
| 2022-12-31 | 39,681,000 | -239,421,000 | -120,883,000 |
| 2023-12-31 | 43,876,000 | -328,066,000 | -300,332,000 |
| 2024-12-31 | 58,839,000 | -463,661,000 | -372,869,000 |
| 2025-12-31 | 74,681,000 | -644,759,000 | -378,277,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2019-12-31 | -2,577.32 | -3,649.39 | -3,654.3 | -3,562.36 |
| 2020-12-31 | 100 | -2,479.2 | -2,549.25 | -1,527.51 |
| 2021-12-31 | 100 | -1,827.75 | -1,780.74 | -1,984.12 |
| 2022-12-31 | -21.66 | -619.26 | -603.36 | -304.64 |
| 2023-12-31 | 2.94 | -797.84 | -747.71 | -684.5 |
| 2024-12-31 | 23.12 | -814.09 | -788.02 | -633.71 |
| 2025-12-31 | -61.96 | -867.87 | -863.35 | -506.52 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Snapshot retrieved 2026-11-10.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.